Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
juMPStart: HMI-203 in Adults with MPS II
NCT05238324Phase 1Withdrawn
- Sponsor
- Homology Medicines
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 2
01
Overview
Phase 1, open-label trial of HMI-203 in mucopolysaccharidosis type II (3 arms), sponsored by Homology Medicines. Primary endpoints: Treatment Emergent Adverse Events at 260 weeks, Adverse Events of Special Interest at 260 weeks and 2 more. Planned start Sep 2022; status: withdrawn.
02
Drugs
HMI-203
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT05238324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238324.